Biomarin Pharmaceutical (BMRN) EBT (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly EBT came in at $141.2 million in Q1 2026, down 40.69% YoY from $238.1 million in Q1 2025, and up 620.03% on a QoQ basis from -$27.2 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) EBT (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of EBT data on file, last reported at $141.2 million in Q1 2026.
- Quarterly EBT fell 40.69% year-over-year to $141.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $385.6 million (down 42.82% YoY) and the FY2025 annual result came in at $482.5 million, down 10.94% from the prior year.
- EBT grew to $141.2 million in Q1 2026, from -$27.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of $297.9 million in Q2 2025 to a low of -$27.2 million in Q4 2025.
- A 5-year average of $88.4 million and a median of $70.8 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT surged 2288.5% — and 2025, when it sank 119.58%.
- Tracing BMRN's EBT over 5 years: stood at -$17.6 million in 2022, then soared by 210.08% to $19.3 million in 2023, then soared by 777.73% to $169.6 million in 2024, then slumped by 116.01% to -$27.2 million in 2025, then jumped by 620.03% to $141.2 million in 2026.
- The last three EBT figures came in at $141.2 million (Q1 2026), -$27.2 million (Q4 2025), and -$26.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 61.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.38 Mn |
| Mar 31, 2026 | 141.20 Mn |
| Dec 31, 2025 | -27.15 Mn |
| Sep 30, 2025 | -26.32 Mn |
| Jun 30, 2025 | 297.87 Mn |
| Mar 31, 2025 | 238.09 Mn |
| Dec 31, 2024 | 169.64 Mn |
| Sep 30, 2024 | 134.44 Mn |
| Jun 30, 2024 | 132.14 Mn |
| Mar 31, 2024 | 105.55 Mn |
| Dec 31, 2023 | 19.33 Mn |
| Sep 30, 2023 | 41.67 Mn |
| Jun 30, 2023 | 70.81 Mn |
| Mar 31, 2023 | 56.76 Mn |
| Dec 31, 2022 | -17.56 Mn |
| Sep 30, 2022 | -1.90 Mn |
| Jun 30, 2022 | 34.85 Mn |
| Mar 31, 2022 | 134.19 Mn |
| Dec 31, 2021 | -66.57 Mn |
| Sep 30, 2021 | -46.16 Mn |